Skip to content

Oncosimis Biotech Private Limited

Hyderabad, Telangana

DPIIT recognised District Healthcare & Lifesciences

In their own words

Developing and production of biosimilar at affordable cost:The global focus on improving healthcare by reducing the costs of production portends an attractive opportunity for manufacturers of biosimilar drugs. Biosimilar viz. mAbs and recombinant proteins are in high demand as they have proved to be highly safe with targeted efficacy. The Oncosimis's R&D approach follow strategic focus on curated process development methodologies that are selective to represent cutting-edge biomedical applications with effective means of cure for a variety of medical conditions with unmet medical needs in patients suffering from both acute and chronic diseases. Being an Indian company, Oncosimis enjoys a lower cost of the facility, human resource, and development costs, apart from helping an immense multitude of our domestic patients with affordable bio-pharmacotherapy.

Written by the company on its public Startup India profile. Not verified by us.

What the record says

DPIIT recognition number
DIPP3037
Registered on Startup India
2018
Self-declared stage
EarlyTraction

www.oncosimis.com

Where this is

District

Hyderabad

Telangana

Startup India records the district. We do not have a street address for this company, and we will not invent one.

No point is drawn, because we do not have one.

Geocode confidence: medium

See all Hyderabad startups on the map

What we do not know

We have no liveness signal for any company on this site: no filings feed, no revenue, no check that the website still resolves. A record existing here means a record exists, not that a business is trading.

Is this your company?

Everything here comes from public government records. If something is wrong, the authoritative place to correct it is the Startup India portal itself, and we will pick the correction up on the next monthly snapshot. To flag an error on our side, write to trust@indianstartupmap.com.

How we built this record